Zoetis Inc. (ZTS) Stock Analysis
Falling Knife setup · Temp Headwind edge
Healthcare · Drug Manufacturers - Specialty & Generic
Sell if holding. Momentum 3.3/10 is below the 5.0 floor at $78.30 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Concentration risk — Geographic: United States (54.0%); Concentration risk — Product: companion animal products (70.0%).
Zoetis is a global animal health company selling medicines, vaccines, and diagnostics for companion animals (70% of revenue) and livestock (29%) across approximately 45 countries. US revenue was $5,097M (54%) and International $4,254M (45%) of ~$9.4B in 2025 revenue, spanning... Read more
Sell if holding. Momentum 3.3/10 is below the 5.0 floor at $78.30 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Concentration risk — Geographic: United States (54.0%); Concentration risk — Product: companion animal products (70.0%). Chart setup: Death cross, below all MAs, RSI 15, MACD bearish. Score 5.8/10, moderate confidence.
Passes 6/8 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, earnings proximity 76d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and death cross (50MA < 200MA). Suitability: moderate.
Recent Developments — Zoetis Inc.
Latest news
- Here's why Zoetis (ZTS) is a strong value stock - MSN — MSN positive
- A Look At Zoetis (ZTS) Valuation As Investors Revisit The Stock After Mixed Recent Returns - Yahoo Finance — Yahoo Finance neutral
- Citi Just Made Zoetis Its Top Pick With a Buy Rating: Is the Pet Economy Boom the Best Trade of 2026? - 24/7 Wall St. — 24/7 Wall St. positive
- Massachusetts Financial Services Co. MA Acquires 126,543 Shares of Zoetis Inc. $ZTS - MarketBeat — MarketBeat neutral
- How Investors May Respond To Zoetis (ZTS) Deepening Its Biologics Focus After World Vaccine Congress Update - Yahoo Fina — Yahoo Finance positive
Generated 2026-05-20T21:06:21Z.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHGeographicUnited States54%10-K Item 1: 'United States (U.S.) with revenue of $5,097 million, or 54% of total revenue for the year ended December 31, 2025'
- HIGHProductcompanion animal products70%10-K Item 1: 'Companion animal products represented approximately 70% of our revenue for the year ended December 31, 2025.'
- MEDIUMProducttop five product lines (Simparica/Simparica Trio, Apoquel, Cytopoint, Librela, ceftiofur)42%10-K Item 1A: 'our five top-selling products and product lines, Simparica/Simparica Trio ... contributed approximately 42% of our revenue in 2025'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
2 floor-breakers
Growth below the gate floor. Component breakdown shows what dragged the score down.static
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Momentum 3.3/10 is below the 5.0 floor at $78.30 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Concentration risk — Geographic: United States (54.0%); Concentration risk — Product: companion animal products (70.0%). Chart setup: Death cross, below all MAs, RSI 15, MACD bearish. Prior stop was $73.40. Score 5.8/10, moderate confidence.
Take-profit target: $112.66 (+42.8% upside). Prior stop was $73.40. Stop-loss: $73.40.
Concentration risk — Geographic: United States (54.0%); Concentration risk — Product: companion animal products (70.0%); Leverage penalty (D/E 2.9): -1.5.
Zoetis Inc. trades at a P/E of 12.9 (forward 10.6). TrendMatrix value score: 7.7/10. Verdict: Sell.
25 analysts cover ZTS with a consensus score of 3.9/5. Average price target: $125.
What does Zoetis Inc. do?Zoetis is a global animal health company selling medicines, vaccines, and diagnostics for companion animals (70% of...
Zoetis is a global animal health company selling medicines, vaccines, and diagnostics for companion animals (70% of revenue) and livestock (29%) across approximately 45 countries. US revenue was $5,097M (54%) and International $4,254M (45%) of ~$9.4B in 2025 revenue, spanning roughly 300 product lines under brands including Simparica, Apoquel, and Cytopoint.